News about a new tablet can raise expectations before essential questions are answered. Research results, regulatory recommendations, authorisation and commercial launch describe different steps. This dated overview provides a way to check new claims. Information was researched on 16 October 2026.
What is confirmed at this date
The current EMA overview for Wegovy describes tablets for adults as well as injectable pens. Older articles portraying the tablet exclusively as a future project are therefore out of date. The overview was updated on 26 August 2026; the linked product information is dated 21 September 2026.
Those dates describe documents, not the first sale in every pharmacy. They do not establish what a particular insurer will pay either. A practical decision needs additional information about the relevant country and exact formulation.
16 October update: a recommendation for Foundayo
On 15 October 2026, the CHMP adopted a positive opinion for Foundayo, containing orforglipron. EMA published it on 16 October. The proposed tablets concern weight management and type 2 diabetes in adults who meet the relevant conditions.
At the date checked here, the European Commission decision was still pending. A committee recommendation is therefore not an already granted EU authorisation or a promise of local availability or reimbursement. Foundayo also has a different active ingredient from Wegovy; the products are not simply interchangeable.
Why “new” can mean several things
A new trial first answers a research question. A recommendation from an EMA committee is a regulatory step. Granted authorisation defines the permitted use for marketing a medicine. A separately confirmed launch or supply enquiry answers the question of whether it can actually be obtained.
Data may also be added after authorisation without expanding the indication. If a report merely says “green light”, find the precise decision and its date. The headline may be less exact than the source it is summarising.
Mounjaro illustrates the distinction
In June 2026, the CHMP completed its assessment of an application concerning serious cardiovascular events in adults with type 2 diabetes and existing cardiovascular disease. It did not recommend a new separate indication, but agreed to include relevant findings in product information.
“New data added to the information” is therefore more accurate than claiming a new approval against heart disease. Check the studied population too. Results concerning diabetes and established disease cannot simply be applied to everyone who would like to lose weight.
Check the original source systematically
Begin with the responsible regulator. An EMA product page includes the current indication, an overview and product information. Switzerland requires a separate check of Swissmedic information. An English-language article does not make US regulatory rules applicable to Europe.
Record the product, ingredient, formulation, country, decision and date. If a key detail is missing, treat the claim as provisional. For study news, add the population, comparator, duration and publication. A manufacturer’s announcement is relevant to what that company plans, but is not an independent assessment of overall clinical value.
Clarify the details before planning treatment
Ask a clinician or pharmacist which presentation is actually available and which treatment purpose is intended. Have costs and possible reimbursement checked separately. An announced launch date cannot guarantee delivery of a specific pack. During shortages, an agreed plan is more useful than an unverified online offer.
Keep a short record of important updates with sources and access dates. You can then recognise when information has become outdated. This article describes the research date given above; it does not claim continuous automatic updating. Current regulatory information remains the reference for subsequent decisions.
Common questions
Does US approval apply in the EU?
No. Authorisation belongs to a particular jurisdiction. Check the regulator responsible for your country, and do not automatically transfer indications or administration instructions.
Can I rely on a launch date in an older report?
An announced date may change. A current decision needs dated information about actual supply. An old search result does not establish present availability.
Sources & further reading
- EMA: Wegovy – EPAR und Produktinformation
- EMA: Mounjaro – EPAR und Produktinformation
- EMA: CHMP meeting highlights, June 2026
- EMA: Foundayo – positive CHMP opinion adopted 15 October 2026
- EMA: New oral GLP-1 medicine – announcement 16 October 2026
- EMA: CHMP meeting highlights 12–15 October 2026
Sources checked:
Questions and experiences
Share a question or a useful experience about this topic. Every contribution is checked before publication. Comments may be written in different languages.
Loading reader contributions…
Opening the form sets a necessary session cookie. No email address is required. Publication is subject to moderation and is not guaranteed. For deletion requests: Contact